Overcoming multiple myeloma drug resistance in the era of cancer ‘omics’
نویسندگان
چکیده
منابع مشابه
Overcoming multiple drug resistance mechanisms in medulloblastoma
INTRODUCTION Medulloblastoma (MB) is the most common malignant paediatric brain tumour. Recurrence and progression of disease occurs in 15-20% of standard risk and 30-40% of high risk patients. We analysed whether circumvention of chemoresistance pathways (drug export, DNA repair and apoptotic inhibition) can restore chemotherapeutic efficacy in a panel of MB cell lines. RESULTS We demonstrat...
متن کاملOvercoming drug resistance in lung cancer.
Anticancer drugs have been explored by means of random screening and demonstrated to be active against not only hematologic malignancies but also some solid tumors. Recent progress in the field of molecular biology has identified many new molecular targets for anticancer drugs. In this review, for example, signal-transduction pathways, which are influenced by newer agents like the taxanes (pacl...
متن کاملCombating and overcoming drug resistance in cancer
While the majority of patients with cancer treated with chemotherapy initially respond to treatment, a sub-group of patients either do not respond or eventually stop responding to the therapy in a phenomenon known as tumor cell resistance. Evidence of many different mechanisms of resistance have been reported in the literature, and it remains a great challenge to delineate the pathways involved...
متن کاملMolecular mechanisms in multiple myeloma drug resistance.
Multiple myeloma (MM) is predominantly an incurable malignancy despite high-dose chemotherapy, autologous stem cell transplant and novel agents. MM is a genetically heterogeneous disease and the complexity increases as the disease progresses to a more aggressive stage. MM arises from a plasma cell, which produces and secretes non-functioning immunoglobulins. Most MM cells are sensitive to prote...
متن کاملThe new concepts on overcoming drug resistance in lung cancer
Lung cancer is one of the most deadly diseases worldwide. The current first-line therapies include chemotherapy using epidermal growth factor receptor tyrosine kinase inhibitors and radiotherapies. With the current progress in identifying new molecular targets, acquired drug resistance stands as an obstacle for good prognosis. About half the patients receiving epidermal growth factor receptor-t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Leukemia & Lymphoma
سال: 2017
ISSN: 1042-8194,1029-2403
DOI: 10.1080/10428194.2017.1337115